Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 410,377 | 406,913 | 433,280 | 403,815 | 457,850 |
| Marketable Securities | 1,217,641 | 1,214,753 | 1,217,954 | 1,208,887 | 1,306,703 |
| Receivables | 461,940 | 445,506 | 444,809 | 489,017 | 457,402 |
| Inventories | 804,276 | 803,693 | 783,369 | 780,517 | 775,818 |
| Other current assets | 28,158 | 32,376 | 38,782 | 26,054 | 25,087 |
| TOTAL | $3,055,620 | $3,056,254 | $3,060,936 | $3,048,330 | $3,146,770 |
| Non-Current Assets | |||||
| PPE Net | 545,304 | 533,767 | 522,364 | 529,007 | 511,389 |
| Investments And Advances | 6,002,635 | 5,099,554 | 8,018,383 | 7,698,070 | 7,218,161 |
| Intangibles | 722,425 | 719,209 | 726,419 | 734,083 | 721,140 |
| Other Non-Current Assets | 277,489 | 279,662 | 281,791 | 289,580 | 298,483 |
| TOTAL | $7,547,853 | $6,632,192 | $9,548,957 | $9,250,740 | $8,749,173 |
| Total Assets | $10,603,470 | $9,688,446 | $12,609,890 | $12,299,070 | $11,895,940 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,262 | 483 | 487 | 486 | 476 |
| Accounts payable and accrued liabilities | 122,185 | 126,693 | 102,750 | 144,625 | 111,859 |
| Accrued Expenses | 146,024 | 132,460 | 146,491 | 139,929 | 154,946 |
| Other current liabilities | 142,013 | 149,916 | 142,427 | 161,621 | 147,801 |
| TOTAL | $497,943 | $486,961 | $466,154 | $522,799 | $558,176 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,200,062 | 1,199,724 | 1,199,381 | 1,199,052 | 1,198,713 |
| aiOther Non-Current Liabilities | 341,550 | 344,512 | 352,232 | 360,591 | 353,300 |
| TOTAL | $2,617,670 | $2,422,698 | $3,092,605 | $3,035,138 | $2,921,569 |
| Total Liabilities | $3,115,613 | $2,909,659 | $3,558,759 | $3,557,937 | $3,479,745 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 27,997 | 27,871 | 28,525 | 28,518 | 29,145 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 8,132,231 | 7,479,059 | 9,644,545 | 9,260,629 | 8,910,921 |
| Other shareholders' equity | -315,704 | -451,004 | -426,041 | -335,574 | -497,181 |
| TOTAL | $7,487,859 | $6,778,787 | $9,051,134 | $8,741,133 | $8,416,198 |
| Total Liabilities And Equity | $10,603,472 | $9,688,446 | $12,609,893 | $12,299,070 | $11,895,943 |